%0 Journal Article
%T Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive EGFR-mutant Non-small Cell Carcinoma.
%A Inomata M
%A Kawashima Y
%A Saito R
%A Morinaga D
%A Nogawa H
%A Sato M
%A Suzuki Y
%A Yanagisawa S
%A Kikuchi T
%A Jingu D
%A Yoshimura N
%A Harada T
%A Miyauchi E
%J Cancer Diagn Progn
%V 4
%N 4
%D 2024 Jul-Aug
%M 38962552
暂无%R 10.21873/cdp.10357
%X <B>UNASSIGNED: </B>Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective for treating non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, higher tumor programmed death ligand-1 (PD-L1) expression is associated with a poor response to EGFR-TKIs, and information on the comparison between afatinib and osimertinib in PD-L1-positive EGFR-mutant NSCLC is scarce.<BR><B>UNASSIGNED: </B>We retrospectively analyzed data of patients with PD-L1-positive EGFR-mutant NSCLC to compare the effectiveness of afatinib and osimertinib.<BR><B>UNASSIGNED: </B>A total of 177 patients were included in the study. The Cox proportion hazard model was adjusted for age, sex, performance status, EGFR mutation status, PD-L1 expression level, and brain metastasis, revealing that there was no significant difference in risk for progression [hazard ratio (HR)=0.99, 95% confidence interval (CI)=0.64-1.53] or death (HR=0.96, 95% CI=0.54-1.73) between afatinib and osimertinib.<BR><B>UNASSIGNED: </B>In conclusion, the EGFR-TKI treatment duration and overall survival after the treatment with afatinib or osimertinib were similar in patients with PD-L1-positive EGFR-mutant NSCLC in the present study.